Riluzole

證據等級: L5

預測適應症: 10 個

Riluzole: From Amyotrophic Lateral Sclerosis to ALS Susceptibility / Motor Neuron Disease Spectrum

Selection note: TxGNN's raw rank #1–#2, #4–#5, #9 predictions (polymicrogyria, spondylometaphyseal dysplasia, trichomegaly-retina syndrome, arthrogryposis syndrome, mitochondrial myopathy) carry no clinical trial or literature evidence, and the evidence pack's own repurposing_rationale explicitly flags them as likely TxGNN score-driven false positives with no mechanistic link (all Hold, decision stage S0). This report instead focuses on rank 8 — "amyotrophic lateral sclerosis, susceptibility to" — the only candidate in the pack with substantive literature support and an actionable decision stage (S3, L1, Proceed with Guardrails).

One-Sentence Summary

Riluzole is the established therapy for Amyotrophic Lateral Sclerosis (ALS), approved based on pivotal trials showing modest survival benefit via inhibition of glutamate-mediated excitotoxicity. The TxGNN model's most clinically credible candidate among 10 predictions is ALS Susceptibility — essentially the known disease itself rather than a novel indication — supported by 20 publications (mechanistic reviews and preclinical studies) but no registered clinical trials in this evidence pull.

Quick Overview

Item	Content
Original Indication	Amyotrophic Lateral Sclerosis (ALS) — not present in `taiwan_regulatory.licenses` (empty); based on well-established external knowledge, confirmed by the pack's own literature (riluzole cited repeatedly as "the only approved ALS drug")
Predicted New Indication	Amyotrophic Lateral Sclerosis, susceptibility to
TxGNN Prediction Score	99.98%
Evidence Level	L1 (per evidence pack scoring — see caveat below)
New Zealand Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Evidence-level caveat: The pack labels this candidate L1, but the 20 literature items actually retrieved by this PubMed query are all reviews/preclinical studies — no RCT is present in the evidence.literature array. The L1 rating implicitly relies on riluzole's well-known pivotal Phase 3 trials (Bensimon 1994, NEJM; Lacomblez 1996, Lancet), which predate ClinicalTrials.gov and are therefore absent from the automated evidence pull. This is a data-completeness gap, not a data-quality error — it should be closed before this evidence level is relied upon for a formal decision.

Why is This Prediction Reasonable?

original_moa is marked as a data gap in the structured drug record, but the repurposing rationale attached to this candidate provides the mechanism: riluzole inhibits presynaptic glutamate release and blocks voltage-dependent sodium channels, reducing excitotoxic injury to motor neurons.

"ALS, susceptibility to" is not a distinct disease area from the original indication — it sits within the same ALS/motor-neuron-disease nosology TxGNN's knowledge graph uses. This explains why the mechanistic link is direct rather than inferential: riluzole's approved use already addresses the pathophysiology this candidate represents. The prediction is best read as the model correctly recovering a known drug-disease relationship, which is useful as a validation signal for the TxGNN pipeline but offers limited incremental repurposing value on its own.

Several other candidates in this pack (rank 3 "lower motor neuron syndrome, late-adult onset," rank 6 "monomelic amyotrophy," rank 7 "Mills syndrome," rank 10 "ALS type 22") sit on the same motor-neuron-disease spectrum and share the same mechanistic rationale, but currently have zero clinical trials or literature and are only at decision stage S1–S2 — these are the candidates that would represent genuine novel repurposing opportunities and warrant future evidence collection.

Clinical Trial Evidence

Currently no related clinical trials registered in this evidence pull. Note: riluzole's pivotal ALS trials (1994–1996) predate the ClinicalTrials.gov registry (est. 2000) and are not captured by automated registry queries.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21128691	2011	Review	CNS Drugs	ALS pathophysiology/diagnosis/management review; riluzole remains the only medication shown to modestly prolong survival
19593125	2009	Review	Current Opinion in Neurology	Riluzole remains the only drug with proven efficacy in ALS despite intensive research into disease mechanisms
22646982	2011	Preclinical Review	Expert Opinion on Drug Discovery	Reviews riluzole as the sole approved ALS therapeutic, improving survival by 2–3 months; discusses need for new agents
20942785	2010	Review	CNS & Neurological Disorders Drug Targets	Genetic determinants of ALS as therapeutic targets; riluzole cited as the only available treatment
9178165	1997	Review	Journal of Neurology	Glutamate hypothesis of motor neuron injury — the core excitotoxicity mechanism riluzole targets
16723044	2006	Review	Expert Reviews in Molecular Medicine	Proposed ALS mechanisms and pathways to treatment, including excitotoxicity
20942786	2010	Review	CNS & Neurological Disorders Drug Targets	ALS diagnosis, pathogenesis, and therapeutic targets overview
8061281	1994	Preclinical	Neuroreport	Direct study of riluzole's neuroprotective effect against ALS CSF-mediated excitotoxicity in neuronal cultures
31108504	2019	Preclinical	Human Molecular Genetics	iPSC-derived ALS motor neurons show altered glutamate receptor/calcium dynamics; notes riluzole's mechanism of glutamatergic inhibition
22763933	2012	Review	Praxis	ALS diagnosis and treatment overview

New Zealand Market Information

Riluzole currently holds no market authorization in New Zealand (market_status: 未上市 / Not Marketed; total_licenses: 0). No product listings are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all flagged as data gaps in this evidence pack — notably DG001, TFDA/local package-insert warnings and contraindications, is marked Blocking for safety pre-assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Riluzole's mechanism and prior ALS approval make this candidate low-risk from a pharmacological-plausibility standpoint, but the evidence base retrieved here is mechanistic/review-level only — no pivotal RCTs or safety data are present in the pack, and the "new indication" substantially overlaps the drug's known approved use rather than representing a distinct novel opportunity.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/local package insert warnings and contraindications before any safety pre-assessment
Resolve DG002: formally source riluzole's MOA from DrugBank into the structured original_moa field
Incorporate riluzole's pivotal Phase 3 RCTs (Bensimon 1994; Lacomblez 1996) into the evidence base, since the current automated pull misses pre-registry trials
Clarify the clinical/regulatory distinction between "ALS" and "ALS, susceptibility to" as a billing/indication code before treating this as an actionable repurposing signal
If pursuing NZ market entry, initiate a Medsafe regulatory pathway assessment given current "not marketed" status
For genuine novel repurposing value, prioritize evidence collection on ranks 3, 6, 7, and 10 (lower motor neuron syndrome, monomelic amyotrophy, Mills syndrome, ALS type 22), which share riluzole's mechanistic rationale but currently lack any clinical trial or literature support
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.